Literature DB >> 9614068

Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines.

C Zhu1, M Johansson, J Permert, A Karlsson.   

Abstract

The cytotoxic anti-cancer purine nucleoside analogs 2-chloro-2'-deoxyadenosine (CdA), 9-beta-D-arabinofuranosylguanine (araG), and 2',2'-difluorodeoxyguanosine (dFdG) are phosphorylated by human mitochondrial deoxyguanosine kinase (dGK) in vitro. We overexpressed dGK as a fusion protein to the green fluorescent protein in the human pancreatic cancer cell lines PanC-1 and MIA PaCa-2 to determine the importance of dGK-mediated nucleoside analog phosphorylation. The transfected cells showed mitochondrial fluorescence patterns, and the mitochondrial locations of endogenous and overexpressed dGK were verified by Western blot analysis of cell extracts with polyclonal anti-dGK antibodies. The increase of dGK activity in the overexpressing cells was approximately 4-fold. These cell lines exhibited increased sensitivity to CdA, araG, and dFdG as compared with the untransfected parent cell lines. This is, to our knowledge, the first demonstration of a correlation between the activity of a mitochondrial deoxyribonucleoside kinase and the cytotoxicity of nucleoside analogs. Our data imply that the dGK activity is rate-limiting for the efficacy of nucleoside analogs in the cell lines investigated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9614068     DOI: 10.1074/jbc.273.24.14707

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Antiviral guanosine analogs as substrates for deoxyguanosine kinase: implications for chemotherapy.

Authors:  A Herrström Sjöberg; L Wang; S Eriksson
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  Mitochondrial toxicity and HIV therapy.

Authors:  A J White
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

3.  Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice.

Authors:  E Arpaia; P Benveniste; A Di Cristofano; Y Gu; I Dalal; S Kelly; M Hershfield; P P Pandolfi; C M Roifman; A Cohen
Journal:  J Exp Med       Date:  2000-06-19       Impact factor: 14.307

4.  Control of fluxes in metabolic networks.

Authors:  Georg Basler; Zoran Nikoloski; Abdelhalim Larhlimi; Albert-László Barabási; Yang-Yu Liu
Journal:  Genome Res       Date:  2016-05-19       Impact factor: 9.043

5.  Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.

Authors:  Meixian Huang; Takeshi Inukai; Kunio Miyake; Yoichi Tanaka; Keiko Kagami; Masako Abe; Hiroaki Goto; Masayoshi Minegishi; Shotaro Iwamoto; Eiji Sugihara; Atsushi Watanabe; Shinpei Somazu; Tamao Shinohara; Hiroko Oshiro; Koshi Akahane; Kumiko Goi; Kanji Sugita
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

Review 6.  Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Authors:  Nikolaos Tsesmetzis; Cynthia B J Paulin; Sean G Rudd; Nikolas Herold
Journal:  Cancers (Basel)       Date:  2018-07-23       Impact factor: 6.639

Review 7.  Purine-Metabolising Enzymes and Apoptosis in Cancer.

Authors:  Marcella Camici; Mercedes Garcia-Gil; Rossana Pesi; Simone Allegrini; Maria Grazia Tozzi
Journal:  Cancers (Basel)       Date:  2019-09-12       Impact factor: 6.639

Review 8.  Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases.

Authors:  An R Van Rompay; Magnus Johansson; Anna Karlsson
Journal:  Pharmacol Ther       Date:  2003-11       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.